All articles by Joshua Silverwood

Joshua Silverwood

Pfizer’s weight loss drug hits primary endpoint in Phase IIb trial

The company will however, not be advancing the twice-daily formulation of danuglipron into Phase III studies.

BioVie reports protocol deviations in Phase III Alzheimer’s trial

Despite violations at 15 out of 39 sites involved in the study, BioVie reported positive data from its trial investigating NE3107.

Health Canada approves third stage of ProJenX’s ALS trial

The health authority has given the go-ahead for Part 1c of the PRO-101 trial investigating the use of prosetin in participants with ALS.

Bayer’s stock drops to new 18-year low after asundexian trial termination

As per recommendations, Bayer will continue to investigate asundexian in a different Phase III trial with stroke patients.

Study finds only 3% of Canadian trials meet all transparency guidelines

A study published by the University of Ottawa found that the majority of Canada-based trials do not meet all reporting requirements.

UK unveils £520m for life sciences as part of Autumn Statement 2023

The UK’s Autumn 2023 Statement takes a special interest in revitalising parts of the life sciences scene.

Innovent’s Phase II mazdutide study shows diabetes patient weight loss

The data from the Phase II trial showed more than a 5% drop in weight in 57.1% of type 2 diabetes patients treated with 6mg of mazdutide.

UK launches medicines scheme with £400m earmarked for clinical trials

The new scheme will launch in 2024 and aims to save the National Health Service (NHS) £14bn over five years.

UK-based clinical trials increase by 4.3% in slow turnaround, ABPI finds

The report published by the Association of the British Pharmaceutical Industry found that UK trials rose from 394 in 2021 to 411 in 2022.